| Document Date: 2013-09-10 17:06:46
Open Document File Size: 242,62 KBShare Result on Facebook
City Irvine / Mississauga / / Company Allergan Inc. / Contract Pharmaceuticals Limited / Ames / / Country Canada / / IndustryTerm applied drug products / body systems / licensed healthcare professional / healthcare professional / mineral oil / / MedicalCondition fetal resorptions / headache / cheilitis / seizures / leukopenia / thrombocytopenia / herpes / numbness / spontaneous abortions / birth defect / stomach upset / hypersensitivity / Erythema (redness) Tingling Skin Dyspepsia Skin Irritation Rash Alopecia Dizziness Folliculitis Hair Ingrown Facial Edema Anorexia Nausea Asthenia Vertigo VANIQA / hearing impairment / contact irritation / Significant dermal irritation / severe inflammatory acne / photosensitization / Carcinogenesis / Folliculitis / Trypanosoma brucei gambiense infection / skin irritation / rosacea / photocontact irritation / skin tumors / irritation / contact dermatitis / dizziness / rash / anemia / Syndrome / African sleeping sickness / / MedicalTreatment hair removal / / / Position PRECAUTIONS General For external use only / pharmacist / Physician / / Product VANIQA / / ProgrammingLanguage C / / ProvinceOrState California / Ontario / / Technology Pharmacokinetics / Pharmacodynamics / / URL www.allergan.com/products/patent_notices / /
SocialTag |
VANIQA® (eflornithine hydrochloride) cream, 13.9% For topical dermatological use only. Not for ophthalmic, oral, or intravaginal use. DESCRIPTION VANIQA® is a cream containing 13.9% (139 mg/g) of anhydrous eflornithine